The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials
AK Abushanab, MT Mousa, MT Mustafa… - Expert Opinion on …, 2023 - Taylor & Francis
Objective To evaluate the clinical efficacy and safety of Capivasertib on patients with solid
tumors. Methods Data from four RCTs were pooled to create a systematic review and meta …
tumors. Methods Data from four RCTs were pooled to create a systematic review and meta …
Long‐term safety with≥ 12 months of pirtobrutinib in relapsed/refractory B‐cell malignancies.
Abstract Four (1%) pts discontinued due to a treatment-related AE, and 1 pt had a fatal
treatment-related AE (Covid-19 pneumonia). BMS Honoraria: Roche, Janssen, Gilead …
treatment-related AE (Covid-19 pneumonia). BMS Honoraria: Roche, Janssen, Gilead …
Perifosine (P) can be combined with docetaxel (T) without dose reduction of either drug
A Cervera, B Bernhardt, JJ Nemunaitis… - Journal of Clinical …, 2006 - ascopubs.org
13066 Background: Perifosine is an alkylphospholipid that modulates several signal
transduction pathways, including Akt, which is often activated in taxane resistant tumors and …
transduction pathways, including Akt, which is often activated in taxane resistant tumors and …
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines
M Schmidt-Hieber, R Dabrowski, A Weimann… - Investigational new …, 2012 - Springer
The novel AKT inhibitor perifosine, a synthetic alkylphospholipid, is currently being
investigated in clinical trials for the treatment of different hematological and oncological …
investigated in clinical trials for the treatment of different hematological and oncological …
A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors
NM Mostafa, YL Chiu, LS Rosen, A Bessudo… - Cancer chemotherapy …, 2014 - Springer
Purpose A phase 1 study was conducted to evaluate the bioavailability and food effect of a
new veliparib formulation in subjects with solid tumors. Methods Subjects (planned: Stage I …
new veliparib formulation in subjects with solid tumors. Methods Subjects (planned: Stage I …
Afuresertib: Protein kinase B (PKB) inhibitor oncolytic
M Conkel, DM Benson Jr - Drugs of the Future, 2014 - access.portico.org
SUMMARY The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) signaling pathway plays key roles in cellular proliferation and survival. Mutations …
(mTOR) signaling pathway plays key roles in cellular proliferation and survival. Mutations …
Antitumor activity of novel Akt inhibitor, perifosine in gastric cancer cell lines
TS Kim, H Song Kim, BR Kwan, CHP Park, HCJ Jeung… - Cancer Research, 2011 - AACR
Abstract Perifosine, a novel phosphatidylinositol-3-kinase (PI3K)/Akt signaling inhibitor is
currently being tested in several phase II/III trials for treatment of major human cancers …
currently being tested in several phase II/III trials for treatment of major human cancers …
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.
J Berlin, RK Ramanathan, JH Strickler… - 2014 - ascopubs.org
2574 Background: Veliparib (V; ABT-888), a potent, competitive poly (ADP-ribose)
polymerase (PARP)-1 and-2 inhibitor enhances the activity of irrinotecan (IRI). This study …
polymerase (PARP)-1 and-2 inhibitor enhances the activity of irrinotecan (IRI). This study …
Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis
P Wang, R Zhao, X Jin, X Zhou, X Xie - Cancer Investigation, 2024 - Taylor & Francis
In this study, we investigate the veliparib‑induced toxicity in cancer patients. Databases were
searched for RCTs treated with veliparib. We found veliparib could increase the risk of …
searched for RCTs treated with veliparib. We found veliparib could increase the risk of …